Astrazeneca Pharma India Ltd vs Walpar Nutritions Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8233 as of 05 May 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Walpar Nutritions Ltd changed from 32.1 on March 2022 to 17.1 on March 2025 . This represents a CAGR of -14.57% over 4 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Walpar Nutritions Ltd changed from ₹ 12.26 crore on March 2022 to ₹ 39.72 crore on March 2025 . This represents a CAGR of 34.16% over 4 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 618.18 crore as compare to the Sep '25 revenue of ₹ 565.26 crore. This represent the growth of 9.36% The revenue of Walpar Nutritions Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 51.44 crore as compare to the Sep '25 ebitda of ₹ 76.06 crore. This represent the decline of -32.37% The ebitda of Walpar Nutritions Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 32.59 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Walpar Nutritions Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Walpar Nutritions Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Walpar Nutritions Ltd

Walpar Nutritions Limited was originally formed and registered as a Partnership Firm in the name and style of 'M/s Walpar Healthcare', pursuant to a Deed of Partnership dated November 16, 2009.
Subsequently, the Constitution of Partnership Firm were changed on March 9, 2015, August 15, 2017 and June 12, 2020 by admission and retirement of Partners. 'M/s.
Walpar Healthcare' was thereafter converted from a erstwhile Partnership Firm to a Public Limited Company as 'Walpar Nutritions Limited' and received a Certificate of Incorporation dated December 4, 2020 from the Central Registration Center, Ministry of Corporate Affairs.
The Company is primarily engaged in manufacturing, marketing and trading of Pharmaceuticals, Nutraceutical, Herbal and Ayurvedic commodities online and offline. The Company made a public issue of 12,00,000 Equity Shares of having Face Value of Rs.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Walpar Nutritions Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Walpar Nutritions Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,583 Cr while Market cap of Walpar Nutritions Ltd is 34 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Walpar Nutritions Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Walpar Nutritions Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Walpar Nutritions Ltd?

As of May 5, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8233.5. On the other hand, Walpar Nutritions Ltd stock price is INR ₹37.0.

How do dividend payouts of Astrazeneca Pharma India Ltd and Walpar Nutritions Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Walpar Nutritions Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.